Table 3. Adverse events (%) by treatment drug (included trials).

AE	Alectinib	Brigatinib	Ceritinib	Crizotinib	p-value*
Any AE (%)	96.7	ND	99.6	97.7	0.022
Any Serious AE (%)	21.6	ND	44.9	31.1	< 0.001
Any Grade 3/4 AE (%)	ND	ND	75.3	43.4	0.009
Diarrhea (%)	13.7	38.2	81.2	56.0	< 0.001
Diarrhea 3/4 (%)	0.6	0.5	5.6	1.7	< 0.001
Nausea (%)	15.3	40.0	73.9	55.3	< 0.001
Nausea 3/4 (%)	0.5	0.9	5.7	1.8	< 0.001
Vomiting (%)	9.8	22.7	60.4	43.9	< 0.001
Vomiting 3/4 (%)	0.6	0.5	5.2	2.0	< 0.001
Constipation (%)	34.1	15.5	24.3	37.1	< 0.001
Constipation 3/4 (%)	0.4	0.5	0.8	1.5	0.37
Fatigue (%)	25.7	27.3	34.5	21.7	0.039
Fatigue 3/4 (%)	1.0	0.5	6.0	2.1	< 0.001
ALT (%)	14.3	ND	46.9	21.8	< 0.001
ALT 3/4 (%)	4.0	ND	22.8	9.1	< 0.001
AST (%)	15.0	14.5	38.8	21.0	< 0.001
AST 3/4 (%)	3.9	0.5	11.4	5.7	0.007
QT (%)	1.2	ND	9.0	14.4	0.025
QT 3/4 (%)	0.8	ND	0.9	3.9	0.003
ILD (%)	0.6	ND	2.4	2.4	0.610
ILD 3/4 (%)	0.4	ND	2.1	2.0	0.310

Abbreviations: AE = Adverse Event; ALT = Alanine Aminotransferase; AST = Aspartate Aminotransferase; ILD = Interstial Lung Disease; ND = No data available;

^*Heterogeneity across treatment was assessed using the between-group Q statistic, p ≤ 0.05 was considered statistically significant.